All In Biotech

Drug Trial Radar · NCT02343042

Selinexor and Backbone Treatments of Multiple Myeloma Patients

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Oct 2015

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Karyopharm Therapeutics IncIndustry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Jan 21, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: * Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete * Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete * Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete * Arm 4: Selinexor + dexamethasone + pomalidomide + bortezomib (SPVd); enrollment complete * Arm 5: Selinexor + dexamethasone + daratumumab (SDd); enrollment complete * Arm 6: Selinexor + dexamethasone + carfilzomib (SKd); enrollment complete * Arm 7: Selinexor + dexamethasone + lenalidomide (SRd) in NDMM; enrollment complete * Arm 8: Selinexor + dexamethasone + ixazomib (SNd); enrollment complete * Arm 9: Selinexor + dexamethasone + pomalidomide + elotuzumab (SPEd); enrollment complete * Arm 10: Selinexor + dexamethasone + belantamab mafodotin (SBd); enrollment complete * Arm 11: Selinexor + dexamethasone + pomalidomide + daratumumab (SDPd); enrollment complete * Arm 12: Selinexor + dexamethasone + mezigdomide (SMd); actively recruiting Selinexor pharmacokinetics: * PK Run-in (Days 1-14): Starting in protocol version 8.0, patients enrolled to any arm in the Dose Escalation Phase (i.e., Arm 4 \[SPVd\], Arm 6 \[SKd\], Arm 8 \[SNd\], Arm 9 \[SPEd\], Arm 10 \[SBd\], and Arm 11 \[SDPd\]) will also first be enrolled to a pharmacokinetics (PK) Run-in period until 9 patients have been enrolled to this period to evaluate the PK of selinexor before and after co-administration with a strong CYP3A4 inhibitor. This run-in period does not apply to Arm 12 (SMd).

Conditions

  • Multiple Myeloma

Interventions

  • SelinexorDrug

    Oral tablets

  • DexamethasoneDrug

    Oral tablets

  • LenalidomideDrug

    Oral capsule

  • PomalidomideDrug

    Oral tablets

  • BortezomibDrug

    Subcutaneous Injection (single use vial)

  • DaratumumabDrug

    Intravenous Infusion

  • CarfilzomibDrug

    Intravenous infusion

  • IxazomibDrug

    Oral capsule

  • ElotuzumabDrug

    Intravenous infusion

  • ClarithromycinDrug

    Tablets

  • Belantamab MafodotinDrug

    Intravenous infusion

  • MezigdomideDrug

    Oral Capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD)Time frame: 12 months
  2. Phase 1 (Dose-escalation): Recommended Phase-2 dose (RP2D)Time frame: 12 months
  3. Phase 1 (Dose-escalation): Maximum Plasma Concentration (Cmax) of SelinexorTime frame: Pre-dose, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)
  4. Phase 1 (Dose-escalation): Area Under the Concentration-time Curve From Time Zero to the Last Non-zero Concentration (AUC0-t) of SelinexorTime frame: Pre-dose, 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)
  5. Phase 1 (Dose-escalation): Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) (AUC0-inf)Time frame: Pre-dose, 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)
  6. Phase 2 (Expansion): Overall response rate (ORR)Time frame: 12 months
  7. Phase 2 (Expansion): Duration of response (DOR)Time frame: 12 months
  8. Phase 2 (Expansion): Clinical Benefit Rate (CBR)Time frame: 12 months

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Active not recruiting

  • Jonnsson Comprehensive Cancer Center / University of Los Angeles

    Los Angeles, California · Active not recruiting

  • Sarah Cannon-Colorado Blood Cancer Institute

    Denver, Colorado · Withdrawn

  • Massachusetts General Hospital

    Boston, Massachusetts · Completed

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Completed

  • Hackensack University Medical Center - John Theurer Cancer Center

    Hackensack, New Jersey · Active not recruiting

  • Columbia University

    New York, New York · Completed

  • Weill Cornell Medicine

    New York, New York · Completed

  • Wilmot Cancer Center/ University of Rochester

    Rochester, New York · Active not recruiting

  • University of North Carolina - Chapel Hill Comprehensive Cancer Center

    Chapel Hill, North Carolina · Active not recruiting

  • Duke Institute of Cancer/ Duke University

    Durham, North Carolina · Recruiting

  • Sarah Cannon- Tennessee Oncology Nashville

    Nashville, Tennessee · Active not recruiting

  • Fred Hutch Cancer Center

    Seattle, Washington · Recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Completed

  • University of Wisconsin School of Medicine and Public Health

    Madison, Wisconsin · Active not recruiting

  • Tom Baker Cancer Center/Alberta Health Services

    Calgary, Alberta, Canada · Completed

  • Cross Cancer Institute / University of Alberta

    Edmonton, Alberta, Canada · Completed

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada · Completed

  • Cancer Care Manitoba

    Winnipeg, Manitoba, Canada · Active not recruiting

  • Memorial Hospital of Newfoundland

    St. John's, Newfoundland and Labrador, Canada · Completed

  • Queen Elizabeth II Health Sciences Center

    Halifax, Nova Scotia, Canada · Active not recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Active not recruiting

  • Maisonneuve-Rosemont Hospital

    Montreal, Quebec, Canada · Completed

  • Royal Victoria Hospital / McGill University

    Montreal, Quebec, Canada · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.